Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulceransinfections

Authors: Daniel P O’Brien, Mike Robson, N Deborah Friedman, Aaron Walton, Anthony McDonald, Peter Callan, Andrew Hughes, Richard Rahdon, Eugene Athan

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Paradoxical reactions from antibiotic treatment of Mycobacterium ulcerans have recently been recognized. Data is lacking regarding their incidence, clinical and diagnostic features, treatment, outcomes and risk factors in an Australian population.

Methods

Data was collected prospectively on all confirmed cases of M. ulcerans infection managed at Barwon Health Services, Australia, from 1/1/1998-31/12/2011. Paradoxical reactions were defined on clinical and histological criteria and cases were determined by retrospectively reviewing the clinical history and histology of excised lesions. A Poisson regression model was used to examine associations with paradoxical reactions.

Results

Thirty-two of 156 (21%) patients developed paradoxical reactions a median 39 days (IQR 20-73 days) from antibiotic initiation. Forty-two paradoxical episodes occurred with 26 (81%) patients experiencing one and 6 (19%) multiple episodes. Thirty-two (76%) episodes occurred during antibiotic treatment and 10 (24%) episodes occurred a median 37 days after antibiotic treatment. The reaction site involved the original lesion (wound) in 23 (55%), was separate to but within 3 cm of the original lesion (local) in 11 (26%) and was more than 3 cm from the original lesion (distant) in 8 (19%) episodes. Mycobacterial cultures were negative in 33/33 (100%) paradoxical episodes. Post-February 2009 treatment involved more cases with no antibiotic modifications (12/15 compared with 11/27, OR 5.82, 95% CI 1.12-34.07, p = 0.02) and no further surgery (9/15 compared with 2/27, OR 18.75, 95% CI 2.62-172.73, p < 0.001). Six severe cases received prednisone with marked clinical improvement. On multivariable analysis, age ≥ 60 years (RR 2.84, 95% CI 1.12-7.17, p = 0.03), an oedematous lesion (RR 3.44, 95% CI 1.11-10.70, p=0.03) and use of amikacin in the initial antibiotic regimen (RR 6.33, 95% CI 2.09-19.18, p < 0.01) were associated with an increased incidence of paradoxical reactions.

Conclusions

Paradoxical reactions occur frequently during or after antibiotic treatment of M. ulcerans infections in an Australian population and may be increased in older adults, oedematous disease forms, and in those treated with amikacin. Recognition of paradoxical reactions led to changes in management with less surgery, fewer antibiotic modifications and use of prednisolone for severe reactions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boyd SC, Athan E, Friedman ND, Hughes A, Walton A, Callan P, McDonald A, O'Brien DP: Epidemiology, clinical features and diagnosis of mycobacterium ulcerans in an Australian population. The Medical journal of Australia. 2012, 196 (5): 341-344. 10.5694/mja12.10087.CrossRefPubMed Boyd SC, Athan E, Friedman ND, Hughes A, Walton A, Callan P, McDonald A, O'Brien DP: Epidemiology, clinical features and diagnosis of mycobacterium ulcerans in an Australian population. The Medical journal of Australia. 2012, 196 (5): 341-344. 10.5694/mja12.10087.CrossRefPubMed
2.
go back to reference Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K, Etuaful S, Klutse E, Quarshie E, van der Werf TS, et al: Histopathologic features of mycobacterium ulcerans infection. Emerging infectious diseases. 2003, 9 (6): 651-656. 10.3201/eid0906.020485.CrossRefPubMedPubMedCentral Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K, Etuaful S, Klutse E, Quarshie E, van der Werf TS, et al: Histopathologic features of mycobacterium ulcerans infection. Emerging infectious diseases. 2003, 9 (6): 651-656. 10.3201/eid0906.020485.CrossRefPubMedPubMedCentral
3.
go back to reference Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C: Selective suppression of dendritic cell functions by mycobacterium ulcerans toxin mycolactone. The Journal of experimental medicine. 2007, 204 (6): 1395-1403. 10.1084/jem.20070234.CrossRefPubMedPubMedCentral Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C: Selective suppression of dendritic cell functions by mycobacterium ulcerans toxin mycolactone. The Journal of experimental medicine. 2007, 204 (6): 1395-1403. 10.1084/jem.20070234.CrossRefPubMedPubMedCentral
4.
go back to reference World Health Organisation: Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. 2012, Geneva, Switzerland World Health Organisation: Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. 2012, Geneva, Switzerland
5.
go back to reference Johnson PD, Hayman JA, Quek TY, Fyfe JA, Jenkin GA, Buntine JA, Athan E, Birrell M, Graham J, Lavender CJ: Consensus recommendations for the diagnosis, treatment and control of mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. The Medical journal of Australia. 2007, 186 (2): 64-68.PubMed Johnson PD, Hayman JA, Quek TY, Fyfe JA, Jenkin GA, Buntine JA, Athan E, Birrell M, Graham J, Lavender CJ: Consensus recommendations for the diagnosis, treatment and control of mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. The Medical journal of Australia. 2007, 186 (2): 64-68.PubMed
6.
go back to reference O'Brien DP, Robson ME, Callan PP, McDonald AH: "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. The Medical journal of Australia. 2009, 191 (10): 564-566.PubMed O'Brien DP, Robson ME, Callan PP, McDonald AH: "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. The Medical journal of Australia. 2009, 191 (10): 564-566.PubMed
7.
go back to reference Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G: Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS neglected tropical diseases. 2011, 5 (8): e1252-10.1371/journal.pntd.0001252.CrossRefPubMedPubMedCentral Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G: Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS neglected tropical diseases. 2011, 5 (8): e1252-10.1371/journal.pntd.0001252.CrossRefPubMedPubMedCentral
8.
go back to reference Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, et al: Paradoxical responses after start of antimicrobial treatment in mycobacterium ulcerans infection. Clin Infect Dis. 2012, 54 (4): 519-526. 10.1093/cid/cir856.CrossRefPubMed Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, et al: Paradoxical responses after start of antimicrobial treatment in mycobacterium ulcerans infection. Clin Infect Dis. 2012, 54 (4): 519-526. 10.1093/cid/cir856.CrossRefPubMed
9.
go back to reference Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M: Clinical efficacy of combination of rifampin and streptomycin for treatment of mycobacterium ulcerans disease. Antimicrobial agents and chemotherapy. 2010, 54 (9): 3678-3685. 10.1128/AAC.00299-10.CrossRefPubMedPubMedCentral Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M: Clinical efficacy of combination of rifampin and streptomycin for treatment of mycobacterium ulcerans disease. Antimicrobial agents and chemotherapy. 2010, 54 (9): 3678-3685. 10.1128/AAC.00299-10.CrossRefPubMedPubMedCentral
10.
go back to reference Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C: Immunosuppressive signature of cutaneous mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. The Journal of infectious diseases. 2009, 200 (11): 1675-1684. 10.1086/646615.CrossRefPubMed Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C: Immunosuppressive signature of cutaneous mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. The Journal of infectious diseases. 2009, 200 (11): 1675-1684. 10.1086/646615.CrossRefPubMed
11.
go back to reference Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, Gama JB, Carvalho MA, Proenca F, Castro AG, Pedrosa J: IFN-gamma-dependent activation of macrophages during experimental infections by mycobacterium ulcerans is impaired by the toxin mycolactone. Journal of immunology. 2010, 184 (2): 947-955. 10.4049/jimmunol.0902717.CrossRef Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, Gama JB, Carvalho MA, Proenca F, Castro AG, Pedrosa J: IFN-gamma-dependent activation of macrophages during experimental infections by mycobacterium ulcerans is impaired by the toxin mycolactone. Journal of immunology. 2010, 184 (2): 947-955. 10.4049/jimmunol.0902717.CrossRef
12.
go back to reference Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C: Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. Journal of immunology. 2010, 184 (3): 1436-1444. 10.4049/jimmunol.0902854.CrossRef Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C: Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. Journal of immunology. 2010, 184 (3): 1436-1444. 10.4049/jimmunol.0902854.CrossRef
13.
go back to reference Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M: Dynamics of the cytokine response to mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clinical and vaccine immunology: CVI. 2009, 16 (1): 61-65. 10.1128/CVI.00235-08.CrossRefPubMed Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M: Dynamics of the cytokine response to mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clinical and vaccine immunology: CVI. 2009, 16 (1): 61-65. 10.1128/CVI.00235-08.CrossRefPubMed
14.
go back to reference Schutte D, Pluschke G: Immunosuppression and treatment-associated inflammatory response in patients with mycobacterium ulcerans infection (Buruli ulcer). Expert opinion on biological therapy. 2009, 9 (2): 187-200. 10.1517/14712590802631854.CrossRefPubMed Schutte D, Pluschke G: Immunosuppression and treatment-associated inflammatory response in patients with mycobacterium ulcerans infection (Buruli ulcer). Expert opinion on biological therapy. 2009, 9 (2): 187-200. 10.1517/14712590802631854.CrossRefPubMed
15.
go back to reference Schutte D, Umboock A, Pluschke G: Phagocytosis of mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. The British journal of dermatology. 2009, 160 (2): 273-283. 10.1111/j.1365-2133.2008.08879.x.CrossRefPubMed Schutte D, Umboock A, Pluschke G: Phagocytosis of mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. The British journal of dermatology. 2009, 160 (2): 273-283. 10.1111/j.1365-2133.2008.08879.x.CrossRefPubMed
16.
go back to reference O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, McDonald A, Holten I, Birrell M, Sowerby JM, Johnson PD, et al: Outcomes for mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. The Medical journal of Australia. 2007, 186 (2): 58-61.PubMed O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, McDonald A, Holten I, Birrell M, Sowerby JM, Johnson PD, et al: Outcomes for mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. The Medical journal of Australia. 2007, 186 (2): 58-61.PubMed
17.
go back to reference Friedman ND, McDonald A, Robson M, O'Brien DP: Corticosteroid use for paradoxical reactions during antibiotic treatment for mycobacterium ulcerans. PLoS neglected tropical diseases. 2012, 6 (9): e1767-10.1371/journal.pntd.0001767.CrossRefPubMedPubMedCentral Friedman ND, McDonald A, Robson M, O'Brien DP: Corticosteroid use for paradoxical reactions during antibiotic treatment for mycobacterium ulcerans. PLoS neglected tropical diseases. 2012, 6 (9): e1767-10.1371/journal.pntd.0001767.CrossRefPubMedPubMedCentral
18.
go back to reference Lawn SD, Meintjes G: Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert review of anti-infective therapy. 2011, 9 (4): 415-430. 10.1586/eri.11.21.CrossRefPubMedPubMedCentral Lawn SD, Meintjes G: Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert review of anti-infective therapy. 2011, 9 (4): 415-430. 10.1586/eri.11.21.CrossRefPubMedPubMedCentral
19.
go back to reference O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, Hughes A, Holten I, Walton A, Athan E: Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of mycobacterium ulcerans: an observational cohort study. PLoS neglected tropical diseases. 2012, 6 (1): e1473-10.1371/journal.pntd.0001473.CrossRefPubMedPubMedCentral O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, Hughes A, Holten I, Walton A, Athan E: Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of mycobacterium ulcerans: an observational cohort study. PLoS neglected tropical diseases. 2012, 6 (1): e1473-10.1371/journal.pntd.0001473.CrossRefPubMedPubMedCentral
20.
go back to reference van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K: Mycobacterium ulcerans infection. Lancet. 1999, 354 (9183): 1013-1018. 10.1016/S0140-6736(99)01156-3.CrossRefPubMed van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K: Mycobacterium ulcerans infection. Lancet. 1999, 354 (9183): 1013-1018. 10.1016/S0140-6736(99)01156-3.CrossRefPubMed
21.
go back to reference Sizaire V, Nackers F, Comte E, Portaels F: Mycobacterium ulcerans infection: control, diagnosis, and treatment. The Lancet infectious diseases. 2006, 6 (5): 288-296. 10.1016/S1473-3099(06)70464-9.CrossRefPubMed Sizaire V, Nackers F, Comte E, Portaels F: Mycobacterium ulcerans infection: control, diagnosis, and treatment. The Lancet infectious diseases. 2006, 6 (5): 288-296. 10.1016/S1473-3099(06)70464-9.CrossRefPubMed
22.
go back to reference Pak J, O'Brien DP, Quek TY, Athan E: Treatment costs of mycobacterium ulcerans in the antibiotic era. International Health. 2012, 4 (2): 123-127. 10.1016/j.inhe.2011.12.005.CrossRefPubMed Pak J, O'Brien DP, Quek TY, Athan E: Treatment costs of mycobacterium ulcerans in the antibiotic era. International Health. 2012, 4 (2): 123-127. 10.1016/j.inhe.2011.12.005.CrossRefPubMed
23.
go back to reference Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, Kemp AS, Robins-Browne RM: Immune response to infection with mycobacterium ulcerans. Infection and immunity. 2001, 69 (3): 1704-1707. 10.1128/IAI.69.3.1704-1707.2001.CrossRefPubMedPubMedCentral Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, Kemp AS, Robins-Browne RM: Immune response to infection with mycobacterium ulcerans. Infection and immunity. 2001, 69 (3): 1704-1707. 10.1128/IAI.69.3.1704-1707.2001.CrossRefPubMedPubMedCentral
24.
go back to reference Portaels F, Silva MT, Meyers WM: Buruli ulcer. Clinics in dermatology. 2009, 27 (3): 291-305. 10.1016/j.clindermatol.2008.09.021.CrossRefPubMed Portaels F, Silva MT, Meyers WM: Buruli ulcer. Clinics in dermatology. 2009, 27 (3): 291-305. 10.1016/j.clindermatol.2008.09.021.CrossRefPubMed
25.
go back to reference Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, Longuet P, Leport C, Vilde JL: Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004, 39 (11): 1709-1712. 10.1086/425742.CrossRefPubMed Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, Longuet P, Leport C, Vilde JL: Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004, 39 (11): 1709-1712. 10.1086/425742.CrossRefPubMed
26.
go back to reference Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V: In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against mycobacterium ulcerans. Antimicrobial agents and chemotherapy. 2006, 50 (6): 1921-1926. 10.1128/AAC.00052-06.CrossRefPubMedPubMedCentral Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V: In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against mycobacterium ulcerans. Antimicrobial agents and chemotherapy. 2006, 50 (6): 1921-1926. 10.1128/AAC.00052-06.CrossRefPubMedPubMedCentral
27.
go back to reference Amsden GW: Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. The Journal of antimicrobial chemotherapy. 2005, 55 (1): 10-21.CrossRefPubMed Amsden GW: Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. The Journal of antimicrobial chemotherapy. 2005, 55 (1): 10-21.CrossRefPubMed
28.
29.
go back to reference Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundote A, Cottin J, Ladikpo T, Ruf T, et al: Oral treatment for mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis. 2011, 52 (1): 94-96. 10.1093/cid/ciq072.CrossRefPubMed Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundote A, Cottin J, Ladikpo T, Ruf T, et al: Oral treatment for mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis. 2011, 52 (1): 94-96. 10.1093/cid/ciq072.CrossRefPubMed
Metadata
Title
Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulceransinfections
Authors
Daniel P O’Brien
Mike Robson
N Deborah Friedman
Aaron Walton
Anthony McDonald
Peter Callan
Andrew Hughes
Richard Rahdon
Eugene Athan
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-416

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.